New Medical Options for the Treatment of Advanced Thyroid Cancer
New Medical Options for the Treatment of Advanced Thyroid Cancer
Sunday, March 24, 2019
Hilton New Orleans Riverside, Grand Ballroom CD
Registration/Breakfast: 5:30 – 5:45 am | Program: 5:45 – 7:45 am
This course is a live CME-certified Ancillary Symposium presented at ENDO 2019, held in New Orleans, LA. This educational activity is supported by an independent medical educational grant from Eisai Co. and Bayer Healthcare Pharmaceuticals LLC. through a collaboration between the Endocrine Society and Medscape Education. These ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC).
PLEASE REGISTER THEN CLICK "START" TO:
EVALUATE SESSIONS
CLAIM CME
DOWNLOAD PRESENTATION SLIDES
PRINT A CERTIFICATE OF ATTENDANCE OR CERTIFICATE OF PARTICIPATION
Target Audience
This activity is intended for endocrinologists and endocrine fellows, primary care physicians, physician’s assistants, nurse practitioners, and other healthcare professionals.
Learning Objectives
Upon completion of this educational activity, learners will be able to:
- Compare and contrast the therapeutic characteristics, efficacy, and safety of ultra-long-acting basal insulins and faster-acting prandial insulins
- Incorporate the emerging evidence into practice regarding combination of GLP-1 agonists and SGLT-2 inhibitors with other non-insulin diabetes therapies in treatment of type 2 diabetes
- Address highly insulin resistant patients using concentrated insulins and combination therapies
- Devise individualized treatment strategies for insulin and non-insulin diabetes therapies using current guidelines and up-to-date trial information
Additional Information
Program Chair
Steven I. Sherman, MD
The University of Texas MD Anderson Cancer Center
Houston, TX
Faculty
Bryan R. Haugen, MD
University of CO Denver
Aurora, CO
Maria Cabanillas, MD
The University of Texas MD Anderson Cancer Center
Houston, TX
DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported no relevant financial relationships during the content development process for this activity: Bryan R. Haugen, MD
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Steven I. Sherman, MD:Consulting, Ignyta, Eisai, Bristol-Myers Squibb, Genzyme
Maria Cabanillas:Advisory Board Member, Ignyta, LOXO, Blueprint; Research Investigator, Genentech, Inc., Eisai, Exelixis, Inc., Kura
The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:
Giuseppe Barbesino, MD: Advisory Boards, Horizon Pharmaceuticals, Ipsen Pharmaceuticals; Spouse, employee of Genzyme
The following SPC members reported relevant financial relationships:
Andrew Ahmann, MD:Research Support, Dexcom, Medtronic; Consultant, Dexcom, Eli Lilly & Company, Horizon CME, MannKind, Novo Nordisk, Sanofi; Speaker, Horizon CME; Principle Investigator, National Institute of Health, T1D Exchange, Trial Net
Joan Han, MD: Research Support, Rhythm Pharmaceuticals; Principle Investigator, Insys Therapeutics, Rhythm Pharmaceuticals
Steven T. Harris, MD:Ad hoc consultant on Advisory Boards, Eli Lilly & Company, Radius Health; Speaker, Amgen, Eli Lilly & Company, Radius Health
Jonathan Purnell, MD: Advisor, Novo Nordisk
Neda Rasouli, MD:Research Support, Novo Nordisk, Boehringer Ingelheim, Rhythm Pharmaceuticals, Elira Therapeutics; Consultant, Intarcia
Amy Rothberg, MD:Spouse, consultant of Merck
Susmeeta Sharma, MD: Speaker, Corcept
The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.
The following SPC members reported no relevant financial relationships:
Beret Ann Casey, MD, Lorena Alarcon-Casas Wright, MD, Neena Natt, MD; Deborah Sellmeyer, MD
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

MAINTENANCE OF CERTIFICATION
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Review your Diplomate ABIM ID Number(s)
In order to earn and report MOC points to the American Board of Internal Medicine (ABIM), you must:
- Provide your board-certification information in your educational profile. Your profile currently contains the following board ID numbers (must be logged in to view):
Your ABIM Number: [current-user:profile-profile:field-number-abim]*
*If your ABIM number is blank or incorrect as shown above, please click the Update Profile button below to add or correct your profile.
Available Credit
- 2.00 ABIM MOC
- 2.00 AMA PRA Category 1 Credits™
- 2.00 CME Certificate of Participation